Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Berk

Showing results (391-400 of 398) with videos related to

Pageof 40
Sort By:
You have reached the last page of results.This site can display upto 398 results.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
JAMA|September 28, 2023
Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyTeresa Coelho, Wilson Marques, Noel R Dasgupta, et al.
Circulation|May 5, 2016
Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisJulian D Gillmore, Mathew S Maurer, Rodney H Falk, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
The New England Journal of Medicine|October 27, 2023
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMathew S Maurer, Parag Kale, Marianna Fontana, et al.
The New England Journal of Medicine|August 30, 2024
Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyMarianna Fontana, John L Berk, Julian D Gillmore, et al.
Muscle & Nerve|January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trialPeter J Dyck, John C Kincaid, P James B Dyck, et al.
Pageof 40

Showing results (391-400 of 398) with videos related to

Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 398 results.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
JAMA|September 28, 2023
Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyTeresa Coelho, Wilson Marques, Noel R Dasgupta, et al.
Circulation|May 5, 2016
Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisJulian D Gillmore, Mathew S Maurer, Rodney H Falk, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
The New England Journal of Medicine|October 27, 2023
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMathew S Maurer, Parag Kale, Marianna Fontana, et al.
The New England Journal of Medicine|August 30, 2024
Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyMarianna Fontana, John L Berk, Julian D Gillmore, et al.
Muscle & Nerve|January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trialPeter J Dyck, John C Kincaid, P James B Dyck, et al.
Pageof 40